#HARMONi: #Ivonescimab + chemo vs chemo in EGFRm NSCLC post–3rd gen TKI - PFS: 6.8 vs 4.4 mo (HR 0.52, p<0.0001) - OS: 16.8 vs 14.0 mo (HR 0.79, p=0.057) Will we see tail of the curve? The role of IO remains to be further defined in EGFRm NSCLC. #wclc2025

☑️#WCLC25 #LCSM Mini Oral Abstract🆙 🔥Nautika1: Clinical Outcomes and Pathologic Regression With Neoadjuvant Alectinib in Resectable Stage IB-IIIB ALK + NSCLC 🎯MPR 17/28 (60.7%), pCR 7/28 (25.0%) 🎙️ Dr. Jay M. Lee @OncoAlert @Larvol @IASLC https://t.co/qYfDgCOHNE

🚨 Not just KRAS & BRAF - FGFR1 joins the club of high-risk CRC alterations ⚡🧬 📊 Study: ESMO Open | 7606 CRC cases (608 in-house + 6998 public) 🔎 Finding: FGFR1 amplification (3.8–4.3%) → dominant FGFR event in CRC 📉 Prognostic hit: DFS: 13 vs 45 mo (HR 2.9) PFS: 16

🫁 NSCLC: Can less be more? Do we always need full-dose, lifelong TKIs? Emerging evidence says maybe not. 🎯 ✨ Trial insights: 💊 Afatinib — LUX-Lung 3/6: 30 mg ≈ 40 mg PFS 🧠 Lorlatinib — CROWN (ALK+): early dose ↓ didn’t affect PFS 🌏 Alectinib — J-ALEX (300 mg BID) vs

Fantastic news for patients! OS benefit with adjuvant abemaciclib for 2 years for high-risk node positive patients. Congratulations to everyone involved with the monarchE trial. Awaiting details at an upcoming meeting. https://t.co/X6woNB4dwK

📣 Updated ESMO #ClinicalPracticeGuideline on early & locally advanced #NSCLC: new systemic treatments, innovative strategies & advanced therapeutic options to personalise #PatientCare & improve outcomes. 🔗 https://t.co/fb1QUVhQv8 #LungCancer #SystemicTherapy #Oncology

Very big news out today-- adjuvant abemaciclib improves overall survival in high-risk ER+ breast cancer at ~7 yrs of f/u! Showing OS benefit in this setting is not easy & nice to see what an incredible impact adj cdk4/6i can have for our patients! https://t.co/pxI4RxPxXz

🔥off the press, now fully published Localised rectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up @Annals_Oncology https://t.co/Ip3o0ija5C 😅all you need to know! @myESMO

📣 Updated ESMO #ClinicalPracticeGuideline recommendations in #MetastaticBreastCancer: focusing on #PrecisionOncology and a #PatientCentricCare, this commentary highlights key updates of the ESMO Living Guideline algorithms, focusing on HR+/HER2- disease. #ESMOGuidelines

Updated treatment recommendations for systemic treatment: from the ESMO Metastatic Breast Cancer Living Guideline† https://t.co/9yP0XCv1XL

Academic read of the day! Crossover in oncology? A concise, open-access, 2-page paper clearly framing when it is is desirable, and when its problematic, by @AlysonHaslam & @VPrasadMDMPH in @Annals_Oncology Seminal 2018 paper and still as relevant! ➡️ https://t.co/aY50RgoBax

@TiansterZhang caught me up on the last decade of #RCC research in 20 mins! @ANZUPtrials #anzup25

🔥BREAKING🆙 Positive OS‼️ ✅FLAURA2: Osimertinib + Chemo vs Osimertinib 🎯"Statistically significant and clinically meaningful improvement in the key secondary endpoint of OS" 🗣️@AstraZeneca @OncoAlert @Larvol #EGFR @EGFRResisters https://t.co/669AbhfHNP

FLAURA-2: Osimertinib + chemo significantly improves OS in EGFR-mutated advanced lung cancer. After MARIPOSA, another option with positive OS data. Current question: MARIPOSA vs FLAURA-2🤔 https://t.co/NJy3RORUQP

ASCO updates stage IV NSCLC with driver mutation guideline #lcsm https://t.co/DWRmSrGdnf

🫁 HMGB1 as a Biomarker for Severe Checkpoint Inhibitor Pneumonitis (CIP): A Prospective Study 📍 Background: Severe checkpoint inhibitor pneumonitis (CIP), particularly grade 3–5 within 3 months of treatment, worsens outcomes in cancer patients. Until now, no validated

🧫 Real-world outcomes of teclistamab in MM with prior BCMA-directed therapy (BCMA-DT): 📌 Among 385 patients, 50% had prior BCMA-DT (CAR-T, ADC, bispecifics). 🔹 Prior BCMA-DT group had:  • Lower ORR: 48.7% vs 61.5% (p=0.012)  • Shorter PFS: 4.6 vs 8.2 months (p=0.017) 🔍 But

🧬🫁 Structure Matters in Compound EGFR-Mutant NSCLC 📊 Multicenter study (n=81) in advanced NSCLC w/ compound EGFR mutations (excluding T790M & exon 20ins): •🧱 Structure-based classification predicts outcomes:  🔹 OS: Unclassified (69.5m) > Classical (47m) > PACC (24.3m)

p-value decoding guide: 0.0000000001 Nobel 🥇 0.049 🍾 0.050 😬 redo math 0.06 “Trending toward…” 0.08 p < 0.10? Why not? ≥0.1 Time for subgroup magic! @drkeithsiau

Important data for LMIC and resource constrained setting from PGI Chandigarh! @DrGPrakash @DrPMPGI Ven 50 mg + Posa generates similar response as Ven 400 mg #leusm @TalhaBadarMD @NitinJainMD @Daver_Leukemia @DrHKantarjian @doctorpemm @jayastuMD @GCC_Cortes @bose_prithviraj